Literature DB >> 8903369

The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy.

M Shindo1, K Hamada, S Koya, K Arai, Y Sokawa, T Okuno.   

Abstract

We examined changes in the hypervariable region 1 of the hepatitis C virus (HCV) RNA that occurred with interferon therapy in 33 patients with chronic hepatitis C to assess the clinical significance of this region. The 33 patients had HCV genotype 1b and were classified into three groups based on serum aminotransferase levels during and after therapy with alpha interferon; long-term responders (n = 9), short-term responders (n = 11), and nonresponders (n = 13). Changes in the genetic heterogeneity of the hypervariable region 1 were determined by using nonisotopic polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP). HCV RNA levels were evaluated by reverse transcriptase PCR and branched DNA probe assays. Changes in sequences were determined by cloning and sequencing analysis. Before therapy, the long-term responders had significantly lower degrees of heterogeneity and lower viral levels than nonresponders. There were no significant differences between short-term and nonresponders. With interferon therapy, viral levels and degree of heterogeneity decreased to a greater extent among long-term and short-term responders than among nonresponders. Sequencing analysis showed that the three groups had similar clone numbers initially, but long-term responders had rather homogeneous viral populations, whereas short-term and nonresponders had heterogeneous populations, but that there were no nucleotide sequences or amino acid alignments that were specific for any group before, during, and 6 months after therapy. Approximately half of short-term and nonresponders received a second course of interferon 7 to 10 months after the initial therapy; all showed an identical response to the second course of therapy regardless of interim changes in the heterogeneity of hypervariable region 1. These findings suggest that (1) patients who were nonresponders or short-term responders had mixed viral populations that had differing sensitivities to interferon, (2) the changes in the hypervariable region 1 (HVR 1) did not affect responsiveness to interferon, and (3) the lower heterogeneity in the HVR 1 was associated with a long-term response to interferon only when the viral levels were low.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8903369     DOI: 10.1053/jhep.1996.v24.pm0008903369

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.

Authors:  Javier Salmerón; Paloma Muñoz De Rueda; Angela Ruiz-Extremera; Jorge Casado; Carlos Huertas; Maria Del Carmen Bernal; Luis Rodríguez; Angel Palacios
Journal:  Dig Dis Sci       Date:  2006-05       Impact factor: 3.199

Review 2.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.

Authors:  J M Pawlotsky; G Germanidis; P O Frainais; M Bouvier; A Soulier; M Pellerin; D Dhumeaux
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Prediction of effect of interferon on chronic hepatitis C.

Authors:  H Takagi; K Takehara; R Shimoda; S Kakizaki; H Takayama; T Abe; T Yamada; Y Hashimoto; S Saitoh; T Matsumoto; A Kojima; J Takezawa; K Yuasa; M Moriguchi; T Sekiguchi; T Nagamine; M Mori
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

5.  High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy.

Authors:  Xiaofeng Fan; Qing Mao; Donghui Zhou; Yang Lu; Jianwei Xing; Yanjuan Xu; Stuart C Ray; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

6.  Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome.

Authors:  Kamila Caraballo Cortés; Osvaldo Zagordi; Karol Perlejewski; Tomasz Laskus; Krzysztof Maroszek; Iwona Bukowska-Ośko; Agnieszka Pawełczyk; Rafał Płoski; Hanna Berak; Andrzej Horban; Marek Radkowski
Journal:  BMC Infect Dis       Date:  2014-07-13       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.